STAT3 inhibition might therefore be a useful single agent or combination therapy in breast cancer while STAT1 inhibition may be more intimately associated with endocrine treatment failure and a useful therapeutic strategy to target resistance. This evidence concerns the gene STAT3 and breast cancer.